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Bronchial colonization by potentially pathogenic microorganisms (PPMs) is often demonstrated in chronic obstructive pulmo-
nary disease (COPD), but culture-based techniques identify only a portion of the bacteria in mucosal surfaces. The aim of the
study was to determine changes in the bronchial microbiome of COPD associated with the severity of the disease. The bronchial
microbiome of COPD patients was analyzed by 16S rRNA gene amplification and pyrosequencing in sputum samples obtained
during stable disease. Seventeen COPD patients were studied (forced expiratory volume in the first second expressed as a per-
centage of the forced vital capacity [FEV1%]median, 35.0%; interquartile range [IQR], 31.5 to 52.0), providing a mean of 4,493
(standard deviation [SD], 2,598) sequences corresponding to 47 operational taxonomic units (OTUs) (SD, 17) at a 97% identity
level. Patients were dichotomized according to their lung function as moderate to severe when their FEV1% values were over the
median and as advanced when FEV1% values were lower. The most prevalent phyla in sputumwere Proteobacteria (44%) and
Firmicutes (16%), followed by Actinobacteria (13%). A greater microbial diversity was found in patients with moderate-to-severe
disease, and alpha diversity showed a statistically significant decrease in patients with advanced disease when assessed by Shan-
non ( 0.528; P 0.029, Spearman correlation coefficient) and Chao1 ( 0.53; P 0.028, Spearman correlation coefficient)
alpha-diversity indexes. The higher severity that characterizes advanced COPD is paralleled by a decrease in the diversity of the
bronchial microbiome, with a loss of part of the resident flora that is replaced by a more restricted microbiota that includes
PPMs.
Bronchial colonization by potentially pathogenic microorgan-isms (PPMs) is a frequent finding in stable chronic obstructive
pulmonary disease (COPD) (1, 2). Positive sputum cultures are
found in a significant proportion of patients, Haemophilus influ-
enzae, Streptococcus pneumoniae, and Moraxella catarrhalis being
the most frequently recovered bacteria (3, 4). Currently available
culture-based techniques are, however, unsuitable for the identi-
fication of a significant portion of the bacteria inhabiting human
mucosal surfaces, which do not grow in the most commonly se-
lective cultures used and may be masked by fast-growing bacteria
(5–7). Culture-independent techniques such as PCR amplifica-
tion and sequencing of the 16S rRNA gene determine the compo-
sition of the bronchial microbiome (1) and may be useful for
defining the relationships between colonizing bacteria andCOPD.
The use of these techniques on samples of bronchial secretions
from COPD patients has demonstrated a rich microbiome in ad-
dition to previously recognized PPMs, with Proteobacteria, Firmi-
cutes, Actinobacteria, and Bacteroidetes being the main recovered
phyla (8–10).
In this study, we aimed to identify severity-related modifica-
tions of the bronchial microbiome in COPD. Bronchial secretions
from stable COPD patients were examined by amplification and
pyrosequencing of the 16S rRNA gene, relating microbiome pat-
terns to lung function.
MATERIALS AND METHODS
Design andpopulation.Across-sectional study focusing on the bronchial
microbiome of stable COPD was performed in outpatients diagnosed
according to Global Initiative for Chronic Obstructive Lung Disease
(GOLD) criteria (11). Participants were examined during stable condi-
tions for 4 weeks, and their sociodemographic and clinical data were
recorded (smoking habits, respiratory symptoms, exacerbation fre-
quency, lung function, and treatments). Exclusion criteria were age40
years, diagnosis of asthma, bronchiectasis, cystic fibrosis, neoplasia,
chronic treatment with oral corticosteroids or immunosuppressive drugs,
and admission to a hospital for respiratory symptoms in the previous 6
months.
Ethics statement.Written informed consent was obtained from each
of the participants in this study. The present study was reviewed and
approved by the Corporació Sanitaria Parc Taulí research ethics commit-
tee in Catalonia, Spain.
Functional variables. Functional characteristics were assessed at en-
rollment by forced spirometry and reversibility testing (12), the 6-min
walking test (13), body mass index, and the multidimensional BODE
index (bodymass index, airflowobstruction, dyspnea, and exercise capac-
ity, as assessed by the 6-min walking test) (14). Forced vital capacity
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(FVC) and forced expiratory volume in the first second (FEV1) weremea-
sured with the same dry rolling seal spirometer (Sibelmed, Sibelgroup,
Barcelona, Spain) and expressed as absolute values (ml) and percentages
of the reference values obtained from age- and height-adjusted selected
volunteers from the Barcelona province (15).
Sputum collection. Sputum was collected for microbiological tests
frompatients in a clinically stable condition.Murray-Washington criteria
were used to identify and select samples representative of bronchial secre-
tions (16, 17). Sputum samples were cultured within 60min of collection,
and the remaining sample was processed for culture-independent micro-
biological techniques (18). Quantitative cultures for PPMs were per-
formed through serial dilutions in selective media according to standard
methods (19) and considered positive when PPMs were recovered at a
concentration of100 CFU/ml. Gram-negative and Gram-positive bac-
teria recognized as agents causing respiratory infections, such as Haemo-
philus influenzae,Haemophilus parainfluenzae, Streptococcus pneumoniae,
Moraxella catarrhalis, Pseudomonas aeruginosa, Staphylococcus aureus,
and Enterobacteriaceae, were considered PPMs.
DNA extraction. Sputum samples were treated for 15 min with an
equal volume of Sputasol (Oxoid,Hampshire, UnitedKingdom) followed
by centrifugation for 15 min at 13,000 g, and genomic DNA extraction
from sputum was performed using a Qiagen DNA blood kit (Qiagen,
Crawley, United Kingdom). Briefly, samples were treated with an in-
house lysis solution containing 47,700 U/ml of lysozyme (Sigma, Poole,
United Kingdom), 100 U/ml of mutanolysin (Sigma, Poole, United King-
dom), and 2 U/ml of lysostaphin (Sigma, Poole, United Kingdom) as
previously described (8). DNAwas quantified in the NanoDropND-1000
spectrophotometer (NanoDrop Technologies, Inc., Wilmington, DE,
USA) and stored at80°C for further determinations.
PCR amplification of the V1/V2 region of the 16S rRNA gene. The
hypervariable regions V1/V2 of the 16S rRNA gene were amplified with
universal bacterial primers and with different bar codes specific for each
sample, following the procedure of McKenna et al. (20). After amplifica-
tion, the products were visualized in 2% agarose gel, purified, and quan-
tified with the QuantiT PicoGreen double-stranded DNA (dsDNA) assay
kit (Invitrogen, Life Technologies, Carlsbad, CA, USA). Samples with dif-
ferent bar code sequences were pooled in equimolar amounts, and pyro-
sequencing was carried out using the Roche 454GS-FLX systemTitanium
chemistry.
Sequences library analysis. As a first quality step, 16S rRNA raw se-
quenceswere analyzedwith themothur softwarepackage1.27 (21) to remove
sequences shorter than 200 bp and chimeras. The quantitative insights into
TABLE 1 Chronic obstructive pulmonary disease patient characteristics
Characteristica All patients
Patients with
moderate-to-severe
disease
Patients with
advanced
disease P valueb
n 17 8 9
Age (median [IQR]) (yr) 69 (66–75) 68 (62–69) 74 (68–77) 0.059
Male (n [%]) 16 (94) 7 (87) 9 (100) 0.279
Smoking (median [IQR]) (pack-yr) 67.5 (40–105) 75 (52–110) 55 (35–117) 0.504
FEV1 postbd (median [IQR]) (%) 35.0 (31.5–52.0) 52.0 (41.5–69.0) 32.0 (29.5–35.0) 0.001
BODE index (median [IQR]) 5 (2–7) 2 (0.25–4) 7 (5.5–8) 0.001
Exacerbationsc (median [IQR]) (n/yr) 1.8 (1.3–2.5) 1.7 (1.3–2.5) 1.9 (1.2–2.5) 0.841
Inhaled corticosteroid use (n [%]) 14 (82) 5 (62.5) 9 (100) 0.082
Antibiotic coursesc,d (median [IQR]) (n/yr) 3.5 (1.9–6.0) 3.6 (2.5–5.0) 3.3 (1.6–6.0) 0.797
Positive PPM sputum culturee (n [%]) 12 (62.5) 5 (62.5) 7 (77.8) 0.625
Haemophilus influenzae 4 (23.5) 1 (12.5) 3 (33.3)
Pseudomonas aeruginosa 5 (29.4) 3 (37.5) 2 (22.2)
Streptococcus pneumoniae 2 (11.8) 1 (12.5) 1 (11.1)
Moraxella catarrhalis 2 (11.8) 2 (25.0) 0
Other 2 (11.8) 0 2 (22.2)
a FEV1 postbd, forced expiratory volume in the first second, postbronchodilator; IQR, interquartile range; BODE, multidimensional scale that includes the items body-mass index,
degree of airflow obstruction, dyspnea, and exercise capacity (14); PPM, potentially pathogenic microorganism.
b Fisher’s exact test, Student t test, or Mann-Whitney U test used as required.
c Average of previous 2 years.
d Antibiotic prescriptions related to any cause (respiratory and nonrespiratory).
e Polymicrobial colonization in three patients.
FIG 1 Principal coordinate (PC) analysis with Bray-Curtis dissimilarity in-
dex. Red and blue dots represent moderate-to-severe and advanced COPD
patients, respectively (Adonis test, P 0.221).
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microbial ecology (QIIME) pipeline (22) was used for de-bar-coding and
quality filtering basedon the characteristics of each sequence as a second step,
removing any low-quality or ambiguous reads with default parameters in
order to obtain taxonomic information. Operational taxonomic units
(OTUs)present in the samples at97%identityweredeterminedandclassified
according to the taxonomy of the Greengenes database (23).
Statistical analysis. Results for categorical variables were expressed as
absolute and relative frequencies, and continuous variables were ex-
pressed asmeans and standard deviations (SD) in normal distributions or
as medians and interquartile ranges (IQR) in abnormal distributions.
Statistical analyses were performed using the SPSS statistical software
package, version 18 (SPSS, Inc., Chicago, IL, USA), the linear discrimina-
tive analysis effect size (LEfSe) (24), and R (http://www.r-project.org),
using the Vegan package to cluster and construct abundance heat maps.
The beta-diversity Bray-Curtis dissimilarity index was used for principal
coordinate analyses and analysis of similarity (Adonis) in order to identify
and compare statistically the bacterial communities visualized in both
groups. Alpha bacterial biodiversity was assessed on the basis of the num-
ber of OTUs observed, using the Chao1 (25) and Shannon (26) indexes,
which estimate the richness and homogeneity, respectively, of the micro-
biome. Alpha- and beta-diversitymetrics were calculated after rarefaction
in QIIME to avoid sequencing effort bias (431 sequences).
Patients were categorized into two groups according to median FEV1%
(35%), consideringpatientswith ahigher value ashavingmoderate-to-severe
disease and the reference and patients with an equal or lower FEV1% as suf-
fering from advanced disease. First, results of sputum cultures in the two
subgroupswere compared (chi-square test). Second, aftermanual removal of
theOTUs present in only one sample from theOTU table, the LEfSemethod
was employed to compare relative abundances (RAs) of bacterial OTUs be-
tween the groups for all taxonomic levels. Finally, correlations among relative
abundances, bacterial diversity, and lung function were assessed (Spearman
correlation test). Statistical tests used in the study were two sided, and a P
value of 0.05 was reported as statistically significant. The predetermined
threshold on the logarithmic linear discriminant analysis (LDA) score for
discriminative features was 2.0.
Nucleotide sequence accession numbers.Bacterial 16S rRNAdata sets
from this study are accessible in the European Nucleotide Archive under the
study accession number PRJEB4144 (accession numbers ERS255709,
ERS255711, ERS255712, ERS255714, ERS255716, ERS255720, ERS255723,
ERS255724, ERS255726, ERS255731, ERS255733, ERS255735, ERS255736,
ERS255738; see http://www.ebi.ac.uk/ena/data/view
/PRJEB4144) and in the MG-RAST server (see http://metagenomics.anl.gov
/) under accession numbers 4481647.3, 4481649.3, 4481655.3, 4481657.3.
RESULTS
Patient characteristics. Seventeen COPD patients, former smok-
ers with an average age of 69 years (IQR, 66 to 65 years) were
included in the study (Table 1). Sputum cultures were positive for
PPMs in more than half of the patients, with a similar prevalence
between moderate-to-severe and advanced disease patients (5/8
[62.5%] versus 7/9 [77.82%]; P 0.062, Fisher’s exact test).
Bronchial microbiome. A mean of 4,493 (SD, 2,598) se-
quences were obtained in the analyzed sputum samples, which
corresponded to 125 OTUs (mean of 47 bacterial OTUs [SD 17]
per sample), at a 97% identity level. Principal coordinate analysis
(PCoA) with the Bray-Curtis beta-diversitymetric was performed
to assess differences between patients with moderate-to-severe
and advanced disease and did not show clustering differences be-
tween the microbial communities of both groups (Adonis statis-
tics, P 0.221) (Fig. 1).
The most prevalent phyla in the sputum samples were Proteo-
bacteria (44%) and Firmicutes (16%) followed by Actinobacteria
(13%), with Bacteroidetes, Fusobacteria, Tenericutes, SR1 incertae,
TM7, and Synergistetes identified in lower proportions (3%)
(Fig. 2). Relative abundances of 50% were found only for Fir-
micutes in 4 patients (23%), and Proteobacteria, which include the
majority of pathogens related to COPD, were found in 7 patients
(41%), with an inverse correlation between both phyla ( 
0.629; P 0.007, Spearman correlation coefficient) (Fig. 3).
FIG 2 Taxonomic identification at phylum level in each sample from moderate-to-severe (labeled with A) and advanced (labeled with B) chronic obstructive
pulmonary disease (COPD) patients.
FIG 3 Scatterplot of Proteobacteria relative abundances and Firmicutes rela-
tive abundances (Spearman correlation coefficient,   0.629 and P 
0.007) in chronic obstructive pulmonary disease (COPD) patients.
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FIG 4 Heat map showing clustering of genera communities and the most predominant genera in chronic obstructive pulmonary disease (COPD) patients with
moderate-to-severe (A) and advanced (B) disease. Sample numbers are listed horizontally along the bottom. The genera are listed vertically on the right. The
relative abundance of each genus is represented by the color key.
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Patients with moderate-to-severe disease showed greater mi-
crobial diversity than patients with advanced disease (Fig. 4), as
shown by the statistically significant correlation between FEV1%
and the bacterial diversity in the sputum, expressed as either Shan-
non (  0.528; P  0.029, Spearman correlation coefficient) or
Chao1 (  0.53; P  0.028, Spearman correlation coefficient)
alpha-diversity indexes (Fig. 5). The higher diversity inmoderate-
to-severe COPD patients was paralleled by a statistically signifi-
cant lower relative abundance of the predominant bacterial OTUs
in the sample (median, 36.7, IQR, 34.4 to 44.0%), compared with
patients with advanced disease (median, 78.6; IQR, 56.8 to 71.9%;
P 0.016, Mann-Whitney test). The comparative analysis of bac-
terial relative abundance (RA) identified 10 OTUs that showed a
significantly higher relative abundance in moderate-to-severe
COPDpatients (P 0.05) (Table 2; Fig. 6). These OTUs belonged
to 5 genera overrepresented in moderate-to-severe COPD, which
reached a median relative abundance of 7.56% (IQR, 0.01 to
43%), much higher than the 0% (IQR, 0 to 0.1%) found in ad-
vanced COPD for these genera.
A total of 3.2% (4/125) of the bacterial OTUs identified in
COPD patients were shared by all participants, independently of
their impairment level. These bacterial OTUs were part of the
genera Rothia, Streptococcus, and Veillonella and represented
12.1% of the observed relative abundance as a whole.
DISCUSSION
This study related bronchial microbiome and the severity of dis-
ease in COPD patients through 16S rRNA gene pyrosequencing
and demonstrated an important decline in bacterial diversity in
patients with lung function impairments that reach the level of
FIG 5 Microbiome diversity in chronic obstructive pulmonary disease (COPD) patients according to lung function by the Shannon index (a) and Chao1 index
(b) (P 0.029,   0.53; P 0.028, Spearman correlation test).
TABLE 2 Discriminative features at different taxonomic levels between moderate-severe and advanced chronic obstructive pulmonary disease
(COPD) patients
Taxonomic levela
Relative abundance (median [IQR]) (n) in:
P
Patients with
moderate-to-severe
disease
Patients with
advanced
disease
Phylum/class/order/family
Proteobacteria/Gammaproteobacteria/Pseudomonadales/Moraxellaceae 7.36 (0.004–37.11) 0 (0) 0.010
Phylum/class/order/family/genus
Firmicutes/Clostridia/Lachnospiraceae/Oribacterium 0.04 (0–0.2) 0 (0–0.009) 0.022
Proteobacteria/Betaproteobacteria/Neisseriales/Neisseriaceae/Eikenella 0.02 (0–0.07) 0 (0) 0.020
Proteobacteria/Gammaproteobacteria/Pseudomonadales/Moraxellaceae/Moraxella 7.36 (0.004–37.11) 0 (0) 0.01
Proteobacteria/Gammaproteobacteria/Pasteurellaceae/Actinobacillus 0.14 (0.005–5.61) 0 (0) 0.002
Phylum/class/order/family/genus/bacterial OTUb
Firmicutes/Clostridia/Lachnospiraceae/Oribacterium/Oribacterium unidentified 0.04 (0.004–0.18) 0 (0–0.06) 0.01
Proteobacteria/Betaproteobacteria/Neisseriales/Neisseriaceae/Eikenella/E. corrodens 0.02 (0–0.07) 0 (0) 0.02
Proteobacteria/Gammaproteobacteria/Pseudomonadales/Moraxellaceae/Moraxella/
Moraxella unidentified
7.36 (0.004–37.11) 0 (0) 0.01
Proteobacteria/Gammaproteobacteria/Pasteurellaceae/Actinobacillus/Actinobacillus
unidentified
0.13 (0.005–5.44) 0 (0) 0.002
Proteobacteria/Gammaproteobacteria/Pasteurellaceae/Actinobacillus/Haemophilus
parahaemolyticus
0.01 (0–0.24) 0 (0) 0.02
a Only results with a statistically significant difference between moderate-to-severe and advanced COPD groups (Mann-Whitney test, P 0.05).
b Bacterial operational taxonomic unit (OTU) identification according to Greengenes database.
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advanced disease. The bronchial microbiome in these patients
changed to a restricted flora that included an overrepresentation
of the bacterial OTU portion of the Proteobacteria phylum, which
included most of the bacteria considered PPMs, and paralleled a
decline in the relative abundance of the bacterial OTU portion of
the Firmicutes phylum.
Data fromour patients confirm the complex bacterial commu-
nity harbored in bronchial secretions from stable COPD patients,
with Proteobacteria, Firmicutes, and Actinobacteria as the main
colonizing phyla. This characteristic microbial pattern disrupts
the continuity of the microbiome pattern observed from the oro-
pharynx to the bronchial tree in normal subjects (27), with the
appearance of PPM usually not found in healthy people (10). The
magnitude of this change parallels the severity of the disease, as
suggested by the inverse correlation between the relative abun-
dances of Firmicutes and Proteobacteria, which include the main
PPMs for the respiratory system, with an overrepresentation of
this pathogenic flora in patients with advanced disease.
Bacterial diversity was clearly higher in themoderate-to-severe
COPD patients, who showed a statistically significant overrepre-
sentation of the genera part of the most prevalent phyla. These
genera represented 12% of the relative abundance in this sub-
group and1% in patients with advanced COPD. Our results do
not correlate with previous data from Pragman and colleagues
(28), who did not find severity-related differences in themicrobial
diversity of the bronchial tree in COPD, a discrepancy probably
attributable to patient selection and sampling. Our study included
patients who showed a wider range of lung function impairment,
increasing the power for identification of differences between
COPD subgroups. Additionally, Pragman et al. analyzed bron-
choalveolar lavage samples, which have shown similarity to bron-
chial biopsy specimens but clear-cut differences in their micro-
biome composition compared with upper bronchial samples such
as sputum and bronchial aspirates (8). Sputum, a sample with
easier recovery and a standardized processing procedure (16, 17),
was selected for our study because of the greater representation of
the whole bronchial tree, considering studies that have found sig-
nificant differences in the microbiome pattern in the bronchial
surface of different bronchi from the same patient (9).
We have shown that the loss of bacterial diversity in advanced
COPD was paralleled by a substitution of the original flora by
colonizing bacteria only marginally present in the bronchial mi-
crobiome of COPDpatients with less severe lung function impair-
ment, a change shown by the decrease in alpha diversity found in
patients with advanced disease. This observation supports a sever-
ity-related change in the bronchial microbiome in COPD, from a
more diverse flora to a restricted microbiome, with an overrepre-
sentation of genera which included PPMs, paralleling the lung
function decline that characterizes advanced COPD. This pattern
of decreased diversity has also been reported in cystic fibrosis (29–
31), suggesting a change to a bacterial flora with a predominance
of some bacterial species that dominate the community (31).
In our study, we have identified a group of bacterial OTUs
present in all patients suffering from this disease, restricted to 3%
of the detected bacterial OTUs, which included bacterial OTUs in
microorganisms from the genera Rothia, Streptococcus, and Veil-
lonella and in the main components of the bronchial microbiome
in healthy subjects (27).Microbial components shared by patients
withmoderate-to-severe and advanced diseasemay be considered
part of the residential flora of their upper bronchial tree or oro-
pharyngeal contamination of the sputum sample, a differentiation
that may be only of marginal importance, considering that a con-
tinuity pattern in the bronchial flora from oropharynx to trachea
has been clearly described in a healthy population (27).
Potentially significant limitations of the study are the limited
number of samples and the differences in historical antibiotic use
inCOPDpatients according to their severity, whichmay influence
the observed microbiome. To minimize this effect, we have in-
cluded in the study only patients who had not been treated with
antibiotics in the previous month, an approach supported by the
demonstrated recovery of bronchial colonization a fewweeks after
antibiotic treatment for an exacerbation (20). We cannot exclude
effects of the technical difficulties inherent in the detection of
certain specific bacteria due to the DNA extraction protocols
and/or amplification primers on the observed results. Accord-
ingly, our results must be considered an initial insight into the
microbiome patterns in COPD, which would need to be con-
firmed in larger cohorts.
In conclusion, we confirm the presence of a rich bronchial
microbiome in COPD in the absence of symptoms of bronchial
infection, with a high prevalence of microorganisms belonging to
the Proteobacteria, Firmicutes, and Actinobacteria phyla. More-
over, our data support the hypothesis that the bronchial micro-
biome in patients suffering from advanced COPD shows a decline
FIG 6 LEfSe (24) rank plot of differentially abundant taxa (bacterial OTUs) at different taxonomic levels in moderate-to-severe versus advanced COPD patients. Statistical
analysis found 10bacterialOTUsoverrepresented inmoderate-to-severeCOPDpatients (A) comparedwith patientswith advanceddisease. unid, unidentified.
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in bacterial diversity, with the substitution of the wide range of
bacteria harbored in patients with less severe impairment by a
more restricted microbiome that includes well-known PPMs that
have only a marginal presence in moderate-to-severe COPD pa-
tients. The substitution of the originally resident microbiome ob-
served in advanced COPD may be partly due to the structural
changes of the bronchial tree that characterize the disease at this
severity stage and may be influenced by the recurrent need of
antibiotic courses for exacerbation treatment. The greater abun-
dance of genera that include PPMs in patients with advanced
COPD may contribute to the maintenance of chronic inflamma-
tory response in the bronchial mucosa, which would further im-
pair the changes in bronchial mucosa of advanced disease. This
vicious circle, accordingly, may be important for the natural his-
tory of the disease.
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